查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1284274

到 2028 年的免疫组织化学 (IHC) 市场预测 - 按产品（试剂盒、抗体、设备、试剂）、按应用（研究用途、诊断和法医）、按最终用户、按地区分类的全球分析

Immunohistochemistry Market Forecasts to 2028 - Global Analysis By Product (Kits, Antibody, Equipment and Reagents), Distribution channel (Research Applications, Diagnosis and Forensic) and End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2022 年全球免疫组织化学染色 (IHC) 市场规模将达到 26 亿美元，预计到 2028 年将达到 42.4 亿美元，预计复合年增长率为8.5%。

免疫组织化学 (IHC) 对于生物标誌物开发至关重要。 免疫组织化学 (IHC) 是一种用于识别抗原和大分子细胞成分的显微技术。 您需要可视化目标蛋白在不同细胞类型、生物週期甚至复杂组织的细胞内的存在和定位。 IHC 的最新进展包括对单个样本中大量蛋白质的灵敏检测以及对蛋白质-蛋白质相互作用的轻鬆检测。 该技术可用于测试药物和诊断各种疾病。

根据世界卫生组织 (WHO) 的情况说明书，2022 年 2 月，癌症是全球死亡的主要原因，2020 年有近 1000 万人死亡，即近 6 人死亡。据说占 1 人。

市场动态：

驱动程序

人口老龄化

随着世界老年人口的迅速增加，与年龄有关的疾病的患病率预计将急剧上升。 世界其他发达国家的老龄化人口数量庞大，而且还在不断增加。 发生感染的机会随着年龄的增长而增加。 因此，随着老年人口的增长，各种疾病的患病率预计将在国际范围内上升。 这被认为是诊断免疫组织化学 (IHC) 市场的关键驱动力。

约束

高度集成

抗体专利到期是全球市场面临的一个大问题。 Merck（德国）和 F. Hoffmann-La Roche（瑞士）的一些一抗正在失去专利保护。 此外，市场进入者必须应对来自世界各国政府的定价压力不断增加和研发产出下降等挑战。 为了克服这些障碍，着名的市场领导者正在收购拥有独特专利产品的中小企业。 这为这些产品进入新的全球市场提供了巨大的财务和分销基础。

市场机会：

新品发布会

领先的市场参与者专注于开发满足当前需求并推动行业发展的技术。 由于推出新的免疫组织化学 (IHC) 产品来解决前面提到的问题，预计该市场将会增长。 顶级公司生产尖端产品，有望成为市场扩张的推动力。 引入这些临床诊断标誌物可能有助于推进免疫肿瘤学癌症治疗的早期药物开发。 由于研究和开发的增加，预计在预测期内市场将快速增长。

威胁

缺乏熟练的专业人员

随着癌症患病率的增加，对临床应用的病理服务的需求也在增加。 大多数对癌症患者进行的测试都是使用组织病理学技术完成的。 然而，这些实验室缺乏训练有素的人员。 相当多的组织病理学家都到了退休年龄，只有有限数量的组织病理学家正在接受新培训。 另一方面，实验室面临着以有限的人员处理不断增加的样本数量的压力。

COVID-19 的影响：

COVID-19 的爆发对免疫组织化学 (IHC) 市场产生了积极影响。 这是由于全球 COVID-19 感染的流行率上升以及越来越多地使用免疫组织化学染色 (IHC) 技术检测 COVI-19 感染。 例如，根据 2020 年 7 月发表在 Laboratory Investigation 上的一篇论文，免疫组织化学染色 (IHC) 和原位杂交 (ISH) 技术被用于检测 SARS-CoV-2。 所有标本均为 IHC 和 ISH 阳性，而所有非 COVID-19 患者标本均为 IHC 和 ISH 阴性。 因此，冠状病毒 (COVID-19) 大流行的影响正在对全球免疫组织化学 (IHC) 市场产生积极影响。

预计预测期内抗体场最大

由于抗体在疾病诊断和药物测试中的重要用途，预计抗体行业将实现利润丰厚的增长。 单克隆抗体和 Fc 融合物、抗体片段和抗体药物偶联物等抗体相关产品在使用方面优于所有其他产品类别。 抗体用于多种应用，包括病理学、神经病理学和血液病理学。 研究抗体越来越多地用于药物发现也是推动抗体市场发展的主要因素。

诊断行业预计在预测期内表现出最高的复合年增长率

在预测期内，诊断部门预计将以最高复合年增长率增长。 免疫组织化学 (IHC) 检测可用于诊断多种慢性疾病，包括自身免疫性疾病、癌症、传染病、心血管疾病、糖尿病和肾臟疾病。 此外，慢性病患病率的增加有望推动诊断行业的发展。 此外，传染病的高流行率和 IHC 测试有利的报销环境也是推动该细分市场份额扩大的因素。

市场份额最高的地区

预计在预测期内，北美将占据最大的市场份额。 北美地区的主导地位可归因于诊断中心和实验室越来越多地使用这种免疫组织化学 (IHC) 仪器。 此外，美国和加拿大等国家有有吸引力的报销规定，鼓励使用自动化设备，从而促进了北美地区 IHC 市场的增长。 此外，预计北美越来越多的癌症患者将增加对这种免疫组织化学 (IHC) 方法的需求。

复合年增长率最高的地区：

预计亚太地区在预测期内的复合年增长率最高。 亚太地区免疫组织化学 (IHC) 市场的快速增长归因于印度、中国、韩国和新加坡等国家的经济繁荣。 此外，印度和中国等国家有大量的患者和大量的临床受试者作为 IHC 研发试验的目标，这导致收入增加。 此外，慢性病的高患病率和人口的快速老龄化也是推动亚太地区免疫组织化学（IHC）行业增长的两个因素。

主要发展：

2021 年 8 月，罗氏获得 FDA 批准 VENTANA MMR RxDx 伴随诊断测试，该测试基于针对 MMR 通路缺陷实体瘤的免疫组织化学染色 (IHC)。 该测试将确定符合 GSK 抗 PD1免疫疗法 JEMPERLI 的患者。

2021 年 8 月，安捷伦的 PD-L1 IHC 22C3 pharmDx 检测在欧洲获得了 CE-IVD 认证，该检测用于识别适合使用 KEYTRUDA 治疗的食管癌患者。

这份报告提供了什么

  • 区域和国家级细分市场的市场份额评估
  • 向新进入者提出战略建议
  • 2020、2021、2022、2025 和 2028 年的综合市场数据
  • 市场趋势（驱动因素、制约因素、机会、威胁、挑战、投资机会、建议）
  • 根据市场预测在关键业务领域提出战略建议
  • 竞争格局映射关键共同趋势。
  • 公司简介，包括详细的战略、财务状况和近期发展
  • 映射最新技术进步的供应链趋势

免费定制优惠：

购买此报告的客户将获得以下免费定制选项之一：

  • 公司简介
    • 其他市场参与者的综合概况（最多 3 家公司）
    • 主要参与者的 SWOT 分析（最多 3 家公司）
  • 区域细分
    • 根据客户的要求对主要国家/地区的市场估计/预测/复合年增长率（注意：基于可行性检查）。
  • 竞争基准
    • 根据产品组合、区域影响力和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 概览
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究来源
    • 二级研究来源
    • 假设

第三章市场趋势分析

  • 司机
  • 约束因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第 5 章全球免疫组织化学 (IHC) 市场：按产品分类

  • 工具包
    • 人体组织 IHC 试剂盒
    • 用于动物组织的 IHC 试剂盒
  • 抗体
    • 一抗
    • 二抗
  • 设备
    • 组织处理系统
    • 载玻片扫描仪
    • 载玻片染色系统
    • 其他设施
  • 试剂
    • 蛋白□
    • 有机溶剂
    • 显色底物
    • 稀释剂
    • 组织学染色
    • 固定试剂
    • 封闭血清和试剂
    • 其他试剂

第 6 章全球免疫组织化学 (IHC) 市场：按应用

  • 研究用途
    • 药物测试
    • 其他研究用途
  • 诊断
    • 自身免疫性疾病
    • 癌症
    • 感染
    • 肾臟疾病
    • 神经系统疾病
    • 其他诊断
  • 取证

第 7 章全球免疫组织化学 (IHC) 市场：按最终用户分类

  • 研究和学术机构
  • 医院和诊断实验室
  • 其他最终用户
    • 製药和生物製药公司
    • 法医研究所
    • 首席风险官

第 8 章整体免疫组织化学 (IHC)按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东和非洲地区

第九章主要进展

  • 合同、伙伴关係、协作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章公司简介

  • Agilent Technologies, Inc.
  • Abcam plc.
  • Bio SB
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • Perkinelmer, Inc.
  • F hoffman La Roche
  • Eagle Biosciences, Inc.
  • CANDOR Bioscience GmbH
  • Elabscience, Inc.
  • Thermofischer Scientific Inc
  • Biogenex Laboratories
Product Code: SMRC23106

According to Stratistics MRC, the Global Immunohistochemistry Market is accounted for $2.60 billion in 2022 and is expected to reach $4.24 billion by 2028 growing at a CAGR of 8.5% during the forecast period. Immunohistochemistry is critical for biomarker development. Immunohistochemistry is a microscopy method used to identify antigens and macromolecular cellular components. It requires visualising the presence and localisation of the target protein in various cell types, biological cycles, and even subcellular localization within complex tissues. Recent advancements in IHC include the sensitive detection of numerous proteins in a single sample and the ease of detecting protein-protein interactions. This technique can be used to test drugs and diagnose a variety of ailments.

According to the World Health Organization (WHO) Fact sheet, February 2022, cancer is a leading cause of death worldwide, and accounted for around 10 million deaths in 2020, or nearly one in six deaths.

Market Dynamics:

Driver:

Rising geriatric population

The prevalence of age-related disorders is expected to climb dramatically as the global geriatric population grows rapidly. Geriatric populations are large and growing in other industrialised economies around the world. The chance of developing infections increases proportionally with age. As a result, it is expected that the prevalence of various diseases would increase internationally as the elderly population grows. This is regarded as an important driving force in the Immunohistochemistry (IHC) market for diagnostic applications.

Restraint:

High degree of consolidation

Antibody patent expiration is a major issue for the global market. Some Merck (Germany) and F. Hoffmann-La Roche AG (Switzerland) primary antibodies are about to lose patent protection. Furthermore, market participants must deal with challenges such as growing price pressure from governments around the world and reduced R&D output. To overcome these barriers, prominent market leaders are acquiring smaller and mid-sized firms with unique patented products. This provides a huge financial and distribution platform for these products to enter new global markets.

Opportunity:

New product launches

Key market leaders focusing on technological developments in response to current needs would boost industry development. The market is expected to grow due to the launch of new immunohistochemistry products to address the previously mentioned issues. The top companies are producing cutting-edge goods that are expected to drive market expansion. The introduction of these clinical diagnostic markers might help to advance early-stage drug development for cancer treatment in immuno-oncology. The market would grow quicker throughout the predicted period due to increased R&D.

Threat:

Dearth of skilled professionals

As the prevalence of cancer has increased, so has the demand for pathology services for clinical applications. The majority of examinations conducted on cancer patients are performed using histopathology technologies. However, there is a shortage of trained personnel in these laboratories. A considerable number of histopathologists have reached retirement age, and only a limited number of new histopathologists are being trained. On the other hand, laboratories are under pressure to process an increasing quantity of specimens with restricted personnel.

COVID-19 Impact:

The COVID-19 outbreak has had a favourable influence on the immunohistochemistry market, owing to an increase in the prevalence of COVID-19 infections worldwide and an increase in the usage of immunohistochemistry techniques for the detection of COVI-19 infections. For example, immunohistochemistry (IHC) and in situ hybridization (ISH) techniques are employed to detect SARS-CoV-2, according to a July 2020 paper published in Laboratory Investigation. All samples were IHC and ISH positive, whereas all specimens from non-COVID-19 patients were IHC and ISH negative. As a result, the impact of the coronavirus (COVID-19) pandemic has remained positive for the global immunohistochemistry (IHC) market.

The antibody segment is expected to be the largest during the forecast period

The antibody segment is estimated to have a lucrative growth, due to the vital usage of antibodies in disease diagnosis and drug testing. Monoclonal antibodies and antibody-related goods such as Fc-fusion, antibody fragments, and antibody-drug conjugates have surpassed all other product classes in terms of usage rate. The antibodies are used in a variety of applications including pathology, neuropathology, and hematopathology. The increasing usage of research antibodies for drug discovery is another major factor driving the development of the antibodies market.

The diagnosis segment is expected to have the highest CAGR during the forecast period

The diagnosis segment is anticipated to witness the highest CAGR growth during the forecast period. Immunohistochemistry tests can be used to diagnose a variety of chronic disorders, including autoimmune diseases, cancer, infectious diseases, cardiovascular diseases, diabetes mellitus, and nephrological diseases. Furthermore, the growing prevalence of chronic disorders is expected to fuel the diagnostics industry. The majority of infectious diseases and the favourable reimbursement environment for IHC tests are additional factors driving the segment's market share growth.

Region with highest share:

North America is projected to hold the largest market share during the forecast period. The dominance of the North American region can be attributable to the growing use of this immunohistochemistry equipment in diagnostic centres and laboratories. Furthermore, attractive reimbursement regulations in countries like as the United States and Canada encourage the use of automated devices, which helps the growth of the IHC market in the North American region. Additionally, an increase in the number of cancer patients from North American countries is expected to increase the need for these immunohistochemical approaches.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. The rapid increase of the Asia-Pacific immunohistochemistry market can be attributed to the economic prosperity of nations such as India, China, South Korea, and Singapore. Furthermore, a big patient pool in countries such as India and China provides a significant number of clinical subjects for IHC R&D tests, leading in revenue growth. Aside from these, the high prevalence of chronic diseases and the rapid ageing of the population are two additional factors driving the growth of the Asia-Pacific Immunohistochemistry Industry.

Key players in the market:

Some of the key players profiled in the Immunohistochemistry Market include Agilent Technologies, Inc., Abcam plc., Bio SB, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Merck KGaA, Perkinelmer, Inc., F hoffman La Roche, Eagle Biosciences, Inc., CANDOR Bioscience GmbH, Elabscience, Inc., Thermofischer Scientific Inc and Biogenex Laboratories.

Key Developments:

In August 2021, Roche received FDA approval for VENTANA MMR RxDx companion diagnostic test based on immunohistochemistry for solid tumors that are deficient in the MMR pathway. The test identifies patients eligible for GSK's anti-PD1 immunotherapy, JEMPERLI.

In August 2021, Agilent received a CE-IVD mark in Europe for its PD-L1 IHC 22C3 pharmDx assay for the identification of oesophageal cancer patients for treatment with KEYTRUDA.

Products Covered:

  • Kits
  • Antibody
  • Equipment
  • Reagents

Applications Covered:

  • Research Applications
  • Diagnosis
  • Forensic

End Users Covered:

  • Research Institutes and Academic Institutes
  • Hospital and Diagnostic Labs
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Immunohistochemistry Market, By Product

  • 5.1 Introduction
  • 5.2 Kits
    • 5.2.1 IHC Kits for Human Tissue
    • 5.2.2 IHC Kits for Animal Tissue
  • 5.3 Antibody
    • 5.3.1 Primary Antibodies
    • 5.3.2 Secondary Antibodies
  • 5.4 Equipment
    • 5.4.1 Tissue Processing Systems
    • 5.4.2 Slide Scanners
    • 5.4.3 Slide staining Systems
    • 5.4.4 Other Equipments
  • 5.5 Reagents
    • 5.5.1 Proteolytic Enzymes
    • 5.5.2 Organic Solvents
    • 5.5.3 Chromogenic Substrates
    • 5.5.4 Diluents
    • 5.5.5 Histological Stains
    • 5.5.6 Fixation Reagents
    • 5.5.7 Blocking Sera and Reagents
    • 5.5.8 Other Reagents

6 Global Immunohistochemistry Market, By Application

  • 6.1 Introduction
  • 6.2 Research Applications
    • 6.2.1 Drug Testing
    • 6.2.2 Other Research Applications
  • 6.3 Diagnosis
    • 6.3.1 Autoimmune diseases
    • 6.3.2 Cancer
    • 6.3.3 Infectious diseases
    • 6.3.4 Nephrological diseases
    • 6.3.5 Neurological diseases
    • 6.3.6 Other Diagnosis
  • 6.4 Forensic

7 Global Immunohistochemistry Market, By End User

  • 7.1 Introduction
  • 7.2 Research Institutes and Academic Institutes
  • 7.3 Hospital and Diagnostic Labs
  • 7.4 Other End Users
    • 7.4.1 Pharma & Biopharma Companies
    • 7.4.2 Forensic Laboratories
    • 7.4.3 CROs

8 Global Immunohistochemistry Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Agilent Technologies, Inc.
  • 10.2 Abcam plc.
  • 10.3 Bio SB
  • 10.4 Bio-Rad Laboratories, Inc.
  • 10.5 Cell Signaling Technology, Inc.
  • 10.6 Danaher Corporation
  • 10.7 F. Hoffmann-La Roche Ltd.
  • 10.8 Merck KGaA
  • 10.9 Perkinelmer, Inc.
  • 10.10 F hoffman La Roche
  • 10.11 Eagle Biosciences, Inc.
  • 10.12 CANDOR Bioscience GmbH
  • 10.13 Elabscience, Inc.
  • 10.14 Thermofischer Scientific Inc
  • 10.15 Biogenex Laboratories

List of Tables

  • Table 1 Global Immunohistochemistry Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Immunohistochemistry Market Outlook, By Product (2020-2028) ($MN)
  • Table 3 Global Immunohistochemistry Market Outlook, By Kits (2020-2028) ($MN)
  • Table 4 Global Immunohistochemistry Market Outlook, By IHC Kits for Human Tissue (2020-2028) ($MN)
  • Table 5 Global Immunohistochemistry Market Outlook, By IHC Kits for Animal Tissue (2020-2028) ($MN)
  • Table 6 Global Immunohistochemistry Market Outlook, By Antibody (2020-2028) ($MN)
  • Table 7 Global Immunohistochemistry Market Outlook, By Primary Antibodies (2020-2028) ($MN)
  • Table 8 Global Immunohistochemistry Market Outlook, By Secondary Antibodies (2020-2028) ($MN)
  • Table 9 Global Immunohistochemistry Market Outlook, By Equipment (2020-2028) ($MN)
  • Table 10 Global Immunohistochemistry Market Outlook, By Tissue Processing Systems (2020-2028) ($MN)
  • Table 11 Global Immunohistochemistry Market Outlook, By Slide Scanners (2020-2028) ($MN)
  • Table 12 Global Immunohistochemistry Market Outlook, By Slide staining Systems (2020-2028) ($MN)
  • Table 13 Global Immunohistochemistry Market Outlook, By Other Equipments (2020-2028) ($MN)
  • Table 14 Global Immunohistochemistry Market Outlook, By Reagents (2020-2028) ($MN)
  • Table 15 Global Immunohistochemistry Market Outlook, By Proteolytic Enzymes (2020-2028) ($MN)
  • Table 16 Global Immunohistochemistry Market Outlook, By Organic Solvents (2020-2028) ($MN)
  • Table 17 Global Immunohistochemistry Market Outlook, By Chromogenic Substrates (2020-2028) ($MN)
  • Table 18 Global Immunohistochemistry Market Outlook, By Diluents (2020-2028) ($MN)
  • Table 19 Global Immunohistochemistry Market Outlook, By Histological Stains (2020-2028) ($MN)
  • Table 20 Global Immunohistochemistry Market Outlook, By Fixation Reagents (2020-2028) ($MN)
  • Table 21 Global Immunohistochemistry Market Outlook, By Blocking Sera and Reagents (2020-2028) ($MN)
  • Table 22 Global Immunohistochemistry Market Outlook, By Other Reagents (2020-2028) ($MN)
  • Table 23 Global Immunohistochemistry Market Outlook, By Application (2020-2028) ($MN)
  • Table 24 Global Immunohistochemistry Market Outlook, By Research Applications (2020-2028) ($MN)
  • Table 25 Global Immunohistochemistry Market Outlook, By Drug Testing (2020-2028) ($MN)
  • Table 26 Global Immunohistochemistry Market Outlook, By Other Research Applications (2020-2028) ($MN)
  • Table 27 Global Immunohistochemistry Market Outlook, By Diagnosis (2020-2028) ($MN)
  • Table 28 Global Immunohistochemistry Market Outlook, By Autoimmune diseases (2020-2028) ($MN)
  • Table 29 Global Immunohistochemistry Market Outlook, By Cancer (2020-2028) ($MN)
  • Table 30 Global Immunohistochemistry Market Outlook, By Infectious diseases (2020-2028) ($MN)
  • Table 31 Global Immunohistochemistry Market Outlook, By Nephrological diseases (2020-2028) ($MN)
  • Table 32 Global Immunohistochemistry Market Outlook, By Neurological diseases (2020-2028) ($MN)
  • Table 33 Global Immunohistochemistry Market Outlook, By Other Diagnosis (2020-2028) ($MN)
  • Table 34 Global Immunohistochemistry Market Outlook, By Forensic (2020-2028) ($MN)
  • Table 35 Global Immunohistochemistry Market Outlook, By End User (2020-2028) ($MN)
  • Table 36 Global Immunohistochemistry Market Outlook, By Research Institutes and Academic Institutes (2020-2028) ($MN)
  • Table 37 Global Immunohistochemistry Market Outlook, By Hospital and Diagnostic Labs (2020-2028) ($MN)
  • Table 38 Global Immunohistochemistry Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 39 Global Immunohistochemistry Market Outlook, By Pharma & Biopharma Companies (2020-2028) ($MN)
  • Table 40 Global Immunohistochemistry Market Outlook, By Forensic Laboratories (2020-2028) ($MN)
  • Table 41 Global Immunohistochemistry Market Outlook, By CROs (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.